Knowledge Partners
McKinsey & Company
Website: www.mckinsey.com
McKinsey is a global management consulting firm committed to helping organizations accelerate sustainable and inclusive growth. We work with clients across the private, public, and social sectors to solve complex problems and create positive change for all their stakeholders. We combine bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for this generation and the next.
MilliporeSigma
Website: www.sigmaaldrich.com
Together with our colleagues, customers and stakeholders, we impact life and health with science. Before researchers can make scientific breakthroughs, they must have access to state-of-the-art tools, services and expertise to perform experiments and engineer new products. That’s where we come in.
We offer one of the broadest portfolios in the industry for scientists, best-in-class products for pharmaceutical development and manufacturing, and a fully integrated service organization to support CDMO and contract testing across traditional and novel modalities.
Our vision is a world where our innovative products, services and digital offerings help create solutions for people globally and a sustainable future for generations to come.
The life science business of Merck KGaA, Darmstadt, Germany, operates as MilliporeSigma in the US and Canada. Merck KGaA, Darmstadt, Germany is a global science and technology company with around 60,000 employees in more than 66 countries.
Lead Partner
Qiagen
Website: digitalinsights.qiagen.com
QIAGEN Digital Insights is the leading provider of genomic and clinical knowledge, analysis and interpretation software and services for scientists and clinicians. With over 25 years of experience in bioinformatics, 140,000 users worldwide, 100,000 citations in scientific papers and 5 million profiled patient cases, our quality knowledge and software will help you gain insights into everything from early discovery to clinical decision-making. Discover our curated knowledge solutions, bioinformatics software and services for better data management, collaboration and actionable insights.
Track Partner
Faculty
Website: faculty.ai
Founded in 2014, Faculty is one of Europe’s leading applied AI companies. Our suite of AI services and products helps organisations design, build, and deploy high-performing AI solutions that deliver measurable impact for their frontline teams. Faculty is also the developer of Faculty Frontier™, a Decision Intelligence platform used by leading pharmaceutical companies to transform decision-making at scale.
Widely recognised as a leader in AI safety, we work closely with the world’s top AI labs, such as OpenAI and Anthropic, to ensure their latest models are safe, human-led, and explainable. Our expertise spans advising Boards, leadership teams, and governments on AI strategy; delivering AI systems that improve critical public services and business outcomes; and equipping organisations with the knowledge and skills they need to thrive in the AI era.
Our PhD-heavy team has delivered hundreds of real-world AI projects across every sector of the economy. Headquartered in London, Faculty remains founder-led and has raised over £40m from investors including The Apax Digital Fund, LocalGlobe, and GMG Ventures.
Gold Partners
Advarra
Website: www.advarra.com
Advarra breaks the silos that impede clinical research, aligning patients, sites, sponsors, and CROs in a connected ecosystem to accelerate trials. Advarra is number one in research review services, a leader in site and sponsor technology, and is trusted by the top 50 global biopharma sponsors, top 20 CROs, and 50,000 site investigators worldwide. Advarra solutions improve collaboration, transparency, and compliance to optimize study design and operations. With unmatched trial operations data, and an ongoing investment in AI innovation, Advarra continues to reimagine what’s possible in clinical research. For more information, visit advarra.com.
Cloudera
Website: www.cloudera.com
Cloudera is a hybrid platform for data, analytics, and AI. With 100x more data under management than other cloud-only vendors, Cloudera empowers global enterprises to transform data of all types, on any public or private cloud, into valuable, trusted insights. Our open data lakehouse delivers scalable and secure data management with portable cloud-native analytics, enabling customers to bring GenAI models to their data while maintaining privacy and ensuring responsible, reliable AI deployments. The world’s largest brands in financial services, insurance, media, manufacturing, and government rely on Cloudera to use their data to solve what once seemed impossible—today and in the future.
Cytiva
Website: www.cytivalifesciences.com/about-us
Cytiva is a global life sciences leader dedicated to helping customers discover and commercialize the next generation of therapeutics. Together, we bring dedicated technical expertise and a broad portfolio of tools and technologies that enable the development, manufacture, and delivery of transformative medicines to patients. Visit cytiva.com to learn more.
GATC Health
Website: link.edgepilot.com/s/7e4ec5d1/LSQ9gYrm3kGMj6puH3zVLA
GATC Health is a California-based tech-bio company pioneering AI in drug discovery and risk modeling. Its Derisq™ AI report predicts drug safety and efficacy outcomes before clinical trials, achieving 91% specificity for off-target risk detection and 86% sensitivity for target activation (independently validated by UC Irvine). Already trusted by Lloyd’s of London for clinical trial insurance, Derisq™ is poised to become the “FICO score” of biotech risk, transforming how investors and regulators evaluate new therapies.
Helix AI
Website: helixai.com
HelixAI is a specialist scientific technology company focused on accelerating research and development for biopharmaceutical organizations. Its platform, JarvisAI, enables scientific teams to design and execute in silico R&D workflows that support a wide range of operations from early-stage drug discovery to scale-up and bioproduction. By integrating scientific data from public, private and client domains along with computational models and AI-driven orchestration, JarvisAI helps researchers explore hypotheses more efficiently and prioritize the most promising drug candidates for further development. This approach supports better, faster decision-making combined with optimization of scientific and wet-lab resources.
HPE
Website: www.hpe.com
HPE (NYSE: HPE) is a leader in essential enterprise technology, bringing together the power of AI, cloud, and networking to help organizations achieve more. As pioneers of possibility, our innovation and expertise advance the way people live and work. We empower our customers across industries to optimize operational performance, transform data into foresight, and maximize their impact. Unlock your boldest ambitions with HPE.
Strangeworks
Website: strangeworks.com
Strangeworks is on a mission to turn computational complexity into real world solutions. With the largest catalog of quantum and quantum-inspired computing resources on an innovative cloud platform backed by computational experts, we make the transformative potential of quantum computing accessible to all. Our AI powered workflows make it easier for enterprises to solve today’s toughest challenges, accelerate breakthroughs, and future-proof their operations. Partnering with customers worldwide, Strangeworks delivers immediate ROI while shaping a smarter, quantum-enabled future.
Vultr
Website: www.vultr.com
Vultr, founded in 2014, is on a mission to empower developers and businesses by simplifying the deployment of infrastructure via its advanced cloud platform. Vultr is strategically located in 32 data centers around the globe and provides frictionless provisioning of Cloud Compute, Cloud GPU, Cloud Storage, Networking, and Bare Metal.
Weave Bio
Website: www.weave.bio
Weave Bio is an AI-native company reimagining how life science organizations navigate regulatory work. Through its core product, the Weave Platform, Weave brings intelligence, structure, and collaboration to every stage of the regulatory process.
The Weave Platform connects people, data, and technology in a unified workspace that combines AI-powered drafting, source-linked data, and configurable workflows. By keeping experts firmly in the loop, it transforms complex, manual regulatory work into transparent, traceable, and collaborative processes.
Built for biotech, pharma, CROs, and regulatory consultants, Weave supports the full regulatory lifecycle—from early development through submission—helping teams move faster, maintain quality, and scale with confidence.
Zephyr AI
Website: www.zephyrai.bio
Zephyr AI is a precision-medicine company unifying enterprise-scale real-world data with multi-modal AI to deliver actionable, biologically interpretable insights across the therapeutic lifecycle—from discovery to clinical deployment. Our software-native, AI-enabled modules predict drug response and reconstruct gene-expression signatures from clinically available DNA-based inputs and drug metadata, and can be fine-tuned to novel therapeutics or diagnostics. Pilots stand up in weeks, informing patient stratification, trial optimization, label expansion, and indication discovery.
PRISM, our SOC 2/HIPAA-aligned data and compute infrastructure, powers rapid cohort construction, synthetic control arms, and real-world validation with intervention-specific risk modeling. Through Aster Insights™ and the ORIEN Total Cancer Care® study, Zephyr provides access to deeply annotated oncology assets—lifetime-consented patients with linked clinical, exome, transcriptome, and whole-slide imaging—to enable fit-for-purpose data generation. We partner with biopharma, diagnostics, and digital-pathology leaders, integrating seamlessly into existing workflows with no new assays required. Together with a rigorous validation engine grounded in real-world outcomes, Zephyr bridges experimental and clinical domains to extract signal from heterogeneous data, de-risk development, and bring effective therapies to patients sooner. Our mission is to make precision medicine accessible and immediate—turning fragmented data into confident, patient-impacting decisions at scale.
ZONTAL
Website: zontal.io
ZONTAL provides the premier data platform tailored for the life science industry. Our platform is at the forefront of digital transformation, delivering innovative solutions that address the intricate challenges faced by large-scale enterprises. Our services streamline IT processes, facilitate the integration of AI/ML applications, accelerate product time-to-market, and enhance regulatory compliance.
With a global presence encompassing the US, Europe, and Asia, ZONTAL is well positioned to offer seamless support to our clients worldwide. Our network of dedicated integration and service partners enables us to deliver our expertise and solutions in any country and across all time zones, ensuring our customers receive unparalleled support wherever they are.
Silver Partners
Alphabiome AI
Website: www.alphabiome.ai
Alphabiome is pioneering a new approach to decoding the microbiome and predicting drug response using advanced AI. Our platform delivers proprietary, IP-protected biomarkers backed by robust human data, ready for direct licensing.
Founded by MIT AI experts and Stanford Nobel Laureates in genetics, the company has already discovered over 100,000 novel biomarkers. The technology has been validated in large-scale animal trials and shown proof-of-concept in humans, with recent breakthroughs in predicting drug efficacy for Crohn’s and Colitis.
Bluenote
Website: www.bluenotehealth.com
Bluenote helps scientists, researchers, and medical writers accelerate critical workflows by 50–75%—so you can spend less time on paperwork and more time advancing life-saving therapies.
Numerion Labs
Website: numerionlabs.ai
Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge ML technologies. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.
MindWalk
Website: www.mindwalkai.com
MindWalk is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT® technology and the LensAI™ platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
Patsnap
Website: www.patsnap.com
Patsnap enables IP and R&D teams to make faster, more informed decisions through advanced AI-powered intelligence. As the global leader in innovation intelligence since 2007, Patsnap provides comprehensive insights that enhance productivity and reduce inefficiencies. Patsnap's domain-specific large language model, trained on extensive proprietary innovation data, integrates with its suite of AI agents to deliver actionable intelligence that increases IP productivity by 75% and reduces R&D waste by 25%. The platform supports seamless collaboration across the complete innovation lifecycle, from patent analysis to competitive intelligence. More than 15,000 companies worldwide, including NASA, PayPal, Sanofi, Dow Chemical, and Wilson Sonsini, trust Patsnap to advance their innovation capabilities through AI.
SPOC Proteomics
Website: spoc.bio
SPOC Biosciences’ sensor-integrated proteome on chip (SPOC) synthesizes 192-1152 proteins (full-length, peptides, miniproteins) or antibody (VHH, scFv, Fab) drugs directly on biosensor chips (SPR, MALDI) for library-scale kinetic affinity screening supporting AI-enabled and traditional antibody discovery pipelines. SPOC KinetiKx datasets include on-rate (ka), off-rate (kd), affinity (KD), and residence time (t1/2). SPOC’s proprietary Protein NanoFactory production system utilizes cell-free expression with simultaneous capture-purification directly onto SPR chips, reducing time and cost for library-scale dataset generation compared to traditional recombinant protein workflows. SPOC HyperKinetiKx SPR Product Suite supports antibody drug discovery efforts for affinity ranking (AffiRank), affinity maturation (AffiBoost), epitope binning (EpiScope), epitope mapping (AminoMap) and polyreactivity screening (ReactiScan). SPOC HyperSynaptiKx SPR Product Suite is specifically designed to produce on-demand, large-scale, high-resolution datasets for validation and training in AI-driven drug discovery and development. HyperSynaptiKx SPR assays include lab-in-the-loop services for wet lab testing in DBTL cycles (BuildLoopIQ) and customer-defined antibody vs target library-on-library screening (ContactIQ).
Bronze Partners
Anima Biotech
Website: www.animabiotech.com
Anima Biotech has built the biology runtime for AI - the Biology GPU.
The Biology GPU is the infrastructure layer that connects how AI thinks with how biology works. It enables AI models to visually compute inside cells in a closed loop of experimental reasoning, revealing the pathways that drive disease.
Powered by a Visual Biology Model trained on 2B+ proprietary cellular pathway images and technology that directly visualizes biological processes and pathways at AI scale, the Biology GPU runs visual experiments inside cells - identifying which pathways are active, how they interact, and where compounds act.
From pathways to targets, mechanisms to compounds, the Biology GPU transforms discovery into a runtime where AI engages directly with biology across the entire lifecycle.
Validated in 20+ discovery programs and collaborations with AbbVie, Takeda, and Lilly, Anima Biotech is defining the runtime infrastructure for AI in biology.
Axio BioPharma
Website: www.axiobiopharma.com
Axio BioPharma is an AI-driven biomanufacturing company revolutionizing how monoclonal antibodies are developed and produced. Headquartered in Madison, WI, Axio combines high-throughput production with proprietary machine learning to predict optimal scalable manufacturing processes in hours - not years. By accelerating development timelines and reducing costs, Axio enables biopharma innovators to bring life-saving therapies to market faster and more efficiently. With deep expertise in antibody manufacturing, protein purification, and bioinformatics, Axio supports a wide range of partners across research, diagnostics, and therapeutics with scalable, U.S.-based production and data-enhanced process design.
BenchiSci
Website: www.benchsci.com
BenchSci is a world leader in AI software for biopharma research and development on a mission to exponentially increase the speed and quality of life-saving R&D to help bring new medicines to patients faster. We apply AI to understand how disease biology works throughout the drug discovery pipeline to solve the number one reason drug discovery projects fail—getting the biology wrong. Our platform, ASCEND, acts as a scalable AI assistant for preclinical organizations, increasing the productivity of the preclinical R&D pipeline across therapeutic areas. Backed by top-tier investors, including Generation Investment Management, iNovia Capital, TCV, F-Prime, Gradient Ventures (Google’s AI fund), and Golden Ventures, BenchSci has raised over $200 million. Our platform accelerates science at 16 top-20 pharmaceutical companies and over 4,500 leading research centers worldwide. For more information about BenchSci, visit www.benchsci.com.
Cradle
Website: www.cradle.bio
Cradle's software helps scientists leverage the latest technological breakthroughs in AI to rewrite biology and unlock new therapeutics, materials, and food sources. Generate novel protein candidates, improve multiple properties simultaneously, and run fewer experiments to create optimized leads.
Cytocast
Website: www.cytocast.com
Cytocast, a TechBio startup based in Budapest, Hungary, accelerates drug discovery by combining bioinformatics, AI, and large‑scale digital‑twin simulations to predict side effects at the start of R&D. Pharma, biotech and CRO teams use the Cytocast technology to de‑risk portfolios earlier and focus resources on safer candidates.
The CYTOCAST DIGITAL TWIN Platform™ models cellular systems to deliver breadth‑first side‑effect profiling for early‑stage small‑molecule programs, including combinations. Proteome‑based simulations reveal how candidates perturb cellular processes and provide actionable evidence to refine chemistries and improve safety. The platform has been validated through pilots with small and mid‑size partners. Currently, the following products are available for the clients’ tailored needs:
- Cytocast Screener™: Rank thousands of compounds by likely side effects to guide early discovery.
- Cytocast Optimizer™: After in vitro/in vivo, refine leads with comparative safety insights for preclinical decisions.
- Cytocast Nominator™: In‑depth analyses to support final candidate selection for trials.
Cytocast has raised €2.5M pre‑seed to date. We are opening a new €5M seed to expand product capabilities and market reach with the goal of adoption at least 10 top‑100 pharma companies by 2027. Cytocast is a proud member of the Alliance for Artificial Intelligence in Healthcare (AAIH) and NVIDIA Inception.
Fisher & Richardson
Website: www.fr.com
Fish helps pioneering life sciences and AI companies to optimize the process of creating new drugs through AI-assisted drug development and discovery. As one of the most experienced AI law firms, Fish aids clients in navigating patent strategy and protection, including application of the "simultaneous conception and reduction to practice doctrine," licensing and collaboration agreements, trade secret protection, regulatory and compliance, litigation and enforcement, and strategic AI planning. Our ability to pair dynamic legal strategies with in-depth Life Sciences industry experience is what separates Fish from other law firms. At Fish, we’ve prosecuted the patents for some of the essential technologies that underpin today’s cutting-edge AI services. AI innovation is advancing faster than the law can catch up, and it takes knowledgeable legal teams to stay on pace. With technical prowess virtually unheard of in the legal industry, Fish’s attorneys have been working with revolutionary technologies for decades. As a result, we know better than most how to protect our clients’ assets when they push the boundaries of IP law.
Genomenon
Website: www.genomenon.com
Genomenon unlocks valuable real-world evidence buried in clinical literature to inform genetic disease and cancer research. Our data and insights empower precision therapeutic companies to optimize clinical trial design, support label expansion, enhance diagnostic patient yield, and streamline regulatory submissions.
Genomenon uses its AI knowledge graph to mine over 10 million full-text scientific articles to characterize patient data reviewed by its team of scientific experts. This comprehensive approach transforms previously inaccessible data into actionable insights, enabling refined disease-prevalence estimates, genotype- phenotype correlation discovery, and clarifying patient demographics and treatment outcomes.
Genomenon's RWE approach unlocks the vast repository of published research, capturing billions of dollars' worth of insights into rare disease and cancer patient presentations, clinical journeys, treatments, and outcomes.
Matterworks
Website: www.matterworks.ai
Matterworks is unlocking predictive biology through an AI-powered platform that immediately uncovers actionable discoveries hidden in LC-MS raw data. Our Large Spectral Model (LSM) has been trained on billions of proprietary raw LC-MS spectra across diverse applications. Built on this foundation, the Pyxis query system leverages the LSM to rapidly identify biomolecules without disparate, time-consuming, and laborious downstream processes.
Available in application-specific configurations, Pyxis transforms conventional manual processing into immediate AI-driven results, expanding the breadth and speed of biomarker discovery, upstream bioprocess optimization, and downstream process development.
Matterworks brings together expertise in AI, software engineering, and analytical chemistry to bridge the gap between raw data and phenotypic endpoints hidden in the dark matter. By developing our AI-powered platform for rapid biomolecule discovery, identification, and concentration determination, we are creating the new standard for researchers, data scientists, and industry leaders to uncover previously unattainable insights and accelerate decision-making across discovery and development.
QC Ware
Website: www.qcware.com
Promethium is a GPU-native, first-principles quantum mechanics (QM) simulation platform developed by QC Ware to accelerate small-molecule drug discovery. Built for both speed and accuracy, Promethium runs up to 100× faster than traditional DFT tools while maintaining quantum-level precision.
Its unique ability to rank-order ligands within 5-25 minutes per compound, delivering FEP-like accuracy, gives medicinal and computational chemists a powerful way to prioritize hits, refine leads, and explore chemical space with unprecedented efficiency. Promethium empowers pharma R&D teams to make faster, more confident decisions in lead optimization and beyond.
Solix Technologies
Website: www.solix.com/solutions/solix-eai-pharma
Solix powers AI-driven drug discovery with a platform built for the real data challenges of pharma and biotech. From early research to clinical execution, we unify siloed data, apply scalable AI and automation, and enable governed, audit-ready intelligence that accelerates therapeutic programs. Our semantic data layer, cloud-native architecture, and purpose-built life sciences apps reduce time-to-insight, improve reproducibility, and future-proof compliance, without forcing teams to “rip and replace” existing systems. With 20+ years in industry, 100+ petabytes of scientific and clinical data processed, and deployments across leading biopharma, Solix enables organizations to move faster, collaborate better, and compete with confidence in a world where data is the molecule.
TetraScience
Website: www.tetrascience.com
TetraScience is the Scientific Data and AI Company. Its Scientific Data Foundry converts the “raw materials” of science into AI-native data, while its Scientific Use Case Factory industrializes AI-enabled workflows across R&D and manufacturing. Tetra AI connects the Foundry and Factory, providing agentic capabilities that guide scientists through complex workflows, surface cross-domain insights, and accelerate scientific outcomes. TetraScience is replatforming the world’s scientific industries for the AI era.
Exhibitors
Bullfrog AI
Website: bullfrogai.com
The Bullfrog AI mission is to de-risk drug development, streamline discovery, and ultimately bring life-changing therapies to patients faster. By combining deep domain expertise with cutting-edge AI technology, BullFrog AI empowers pharmaceutical and biotech innovators to navigate complexity, reduce uncertainty, and improve outcomes in the pursuit of next-generation treatments.
BullFrog AI is transforming the future of drug discovery and development by harnessing the power of artificial intelligence and machine learning to address some of the industry’s most critical challenges, to include clinical trial optimization, target ID, and data analysis. At the core of BullFrog AI’s innovation is bfPREPTM and bfLEAP™, the company’s proprietary causal AI platform designed to analyze and interpret complex biological and clinical data with precision. Unlike traditional machine learning methods that often reveal correlations without context, bfLEAP™ uncovers causal relationships, enabling researchers to identify meaningful biological insights that drive more effective therapeutic strategies.
Through strategic collaborations with leading research institutions and biopharma organizations, BullFrog AI integrates multi-omic, preclinical, and clinical datasets to accelerate drug development pipelines. By transforming unstructured, fragmented data into harmonized, analysis-ready datasets, BullFrog AI enables scientists to uncover novel drug targets, refine trial design, and enhance patient stratification. This capability matters because more reliable insights at earlier stages directly reduce costly late-stage trial failures, shorten development timelines, and increase the likelihood of bringing effective therapies to patients who need them most.
Coriolis Pharma
Website: www.coriolis-pharma.com
Coriolis Pharma is a global Contract Research and Development Organization (CRDO), specializing in liquid and lyophilized drug products. We offer integrated drug development, analytical, and manufacturing services for biologics, gene and cell therapies, and vaccines—supporting your program from preclinical to commercial stages under both R&D and GMP.
Our scientists combine deep formulation expertise with in silico modeling tools to accelerate development, reduce risk, and optimize stability from the start. This data-driven approach enhances decision-making and supports robust, scalable solutions.
Why Coriolis?
- Full lifecycle support from early development to commercialization
- Proven expertise in advanced modalities and digital tools
- Laboratories in Europe and USA
- Client-focused collaboration and scientific excellence
iMOL
Website: www.stonewise.ai
IMOL is an AI-driven company focused on novel drug discovery, and became a member of JLABS Singapore in 2024.
Leveraging industry expertise, breakthroughs in AI technology, in-depth data governance capabilities, and robust software and hardware capabilities, the company has developed a multimodal AI 3D generation model focused on small molecules. Based on the GPT/Transformer architecture and integrated with geometric deep learning technology, this model can accurately generate molecules that match the targets and extend to multiple modalities. In addition, the company can provide customized solutions for the industry.
Currently, pharmaceutical enterprises and research institutions worldwide utilize this AI platform for early-stage R&D activities.
Quantori
Website: quantori.com
Quantori is the premier digital services partner for life sciences and healthcare companies worldwide. With deep domain expertise and end-to-end capabilities in AI, data science, and software engineering, we help biopharma innovators accelerate R&D pipelines and bring transformative therapies to patients worldwide.
Via Scientific
Website: www.viascientific.com
Via Scientific helps life science teams operationalize AI in biology. Our Foundry platform radically simplifies enterprise-scale multi-omics processing and analytics.
Teams use Foundry to accelerate model development, from LLM-assisted data interpretation to generative multi-omics analysis, all in secure, containerized environments.
For scientists building and deploying machine learning in live drug-discovery programs, Foundry provides the infrastructure layer that lets scientists focus on discovery – running larger, more complex analyses securely, reproducibly, and without the burden of infrastructure management.
We don’t sell AI for drug discovery – we enable the people doing it to move faster, collaborate securely, and scale confidently.
WuXi AppTec
Website: www.wuxiapptec.com
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry worldwide to advance discoveries and deliver groundbreaking treatments to patients. WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development, and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development, and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions.
Tech Test Lab Partners
Examol Corporation
Website: examol.io
Examol accelerates drug discovery for challenging targets and advanced modalities through physics-based simulations that capture millisecond to minute timescales. Their technology enables binding kinetics predictions, identification of transient druggable pockets, and training data generation for generative AI models that improve drug design. The platform has successfully predicted minute-scale residence times, optimized PROTAC degraders, and revealed transient binding sites invisible to conventional methods.
Helical
Website: www.helical-ai.com
Helical is the in-silico AI lab for pharma, powered by Bio Foundation Models. We enable pharma R&D teams to uncover novel targets and biomarkers, stratify patients, and accelerate RNA therapeutic design through virtual experiments that run in hours, not months.
Already used by leading pharma companies, Helical turns Bio Foundation Models into a true experimentation system, enabling teams to personalize models, and run virtual hypotheses at scale before committing to the wet lab.
Salt AI
Website: www.salt.ai
- Salt AI is a contextual AI platform purpose-built for the life sciences. We connect data, models, and tools into a unified system that acts intelligently across the pharmaceutical, biotech, and healthcare value chain—transforming the way scientists and enterprises deploy and scale AI.
- Our platform makes the “black box” of enterprise AI transparent and interoperable, enabling seamless collaboration between specialized models and proprietary datasets. Salt’s native compute optimization ensures efficiency and performance—platform benchmarks show workloads like AlphaFold running up to 22× faster than out-of-the-box implementations.
- Designed for both technical and scientific users, Salt offers a visual-first, code-in/code-out interface that combines the flexibility of coding environments with the accessibility of low-code tools. Our engineering teams deploy Salt directly into customers’ preferred infrastructure and support solution development and rollout within 90 days.
- Salt AI is already driving real-world impact—recently accelerating the translation of oncology-focused computational proteins into the wet lab in partnership with the Ellison Medical Institute.
